EDITORIAL
Europe cannot afford to wait any longer for cleaner air
Despite recent progress, lung cancer remains deadly and difficult to treat — and preventable, to a much greater extent with the right actions to improve the quality of the air we breathe
HIGHLIGHTS FROM ELCC 2024
Are ADCs in lung cancer living up to expectations?
High rates of adverse events in the experimental setting seem to limit the potential of antibody–drug conjugates for patients with NSCLC
Post-progression data confirm the benefits of novel combinations for EGFR-mutated NSCLC
Analyses of FLAURA2, MARIPOSA and MARIPOSA-2 trials provide further guidance on treatment choices for advanced lung cancer, but questions remain about optimal sequencing
Could subcutaneous administration become the standard for immunotherapy?
Two studies add further evidence of the advantages of this route for delivering immune checkpoint inhibitors for patients and healthcare sustainability
HIGHLIGHTS FROM THE ESMO SARCOMA and RARE CANCERS CONGRESS 2024
A new combination treatment shows early promise in GEP-NECs
Lurbinectedin and irinotecan demonstrate a synergic clinical effect in patients with neuroendocrine carcinomas of gastroenteropatic primary site after chemotherapy failure
Can sarcomas benefit from targeted treatments active in other tumour types?
Two studies in sarcoma explore the promise of ADCs and theranostics realised in different tumours.
Studies provide further evidence to support continued imatinib in two different GIST indications
Uninterrupted imatinib is essential to optimise outcomes in metastatic and high-risk resected GIST
OTHER NEWS
BRCA mutations are associated with worse treatment outcomes in mCRPC
In patients with metastatic castration-resistant prostate cancer, early genetic testing may help personalise treatments in the first-line as a study suggests
A multimodal liquid biopsy analysis shows promise in monitoring response to immunotherapy
A study shows that early kinetics in DNA methylation and fragment quantity in plasma can predict response to pembrolizumab in patients with advanced solid tumours
Most women report poor sexual health after a diagnosis of breast cancer
However, patients’ sexual concerns are often unaddressed in oncology, a study suggests
COLUMNS
Use of ctDNA as a surrogate in early clinical drug development – nearing its end point?
Several key issues including standardisation and validation of ctDNA response criteria for predicting clinical outcomes in oncology still need to be addressed
A net-zero emission oncology is made by small actions
Green oriented practical tips encompass a reorganisation of waste disposal and pathology testing at single centres which may result in a reduction of the carbon footprint of cancer care globally
How to integrate the social determinants of health in cancer care
Increasing data show that they are indicators of inequitable environments which may negatively impact on cancer outcomes, but more efforts are needed to properly assess them in oncology